Nuvalent Insiders Sell 12,835 Shares at $97.3 for $1.25M, Holdings Drop up to 8.9%
On January 5 three Nuvalent insiders Deborah Ann Miller, Christopher Durant Turner and CFO Alexandra Balcom sold a combined 12,835 shares at roughly $97.3 per share for total proceeds of about $1.25 million. The insider holdings decreased by 4.8% to 8.9% per filer, signaling potential reevaluation of stock value.
1. Insider Transaction Activity
Nuvalent’s Chief Medical Officer, Deborah Ann Miller, initiated a series of equity disposals in early January, selling a total of 6,952 shares across January 5th and 6th. The two transactions generated combined proceeds of approximately $676,154 and reduced her total holdings by 13.03%, bringing her stake to 40,134 shares. This represents a notable shift in insider positioning, as Miller’s cumulative sales since mid-October amount to over 81,000 shares, eroding her ownership by nearly 25%. All trades were reported via SEC filings, underscoring heightened insider liquidity over the past quarter.
2. Institutional and Analyst Developments
Nuvalent’s market cap stands near $7.6 billion, and the company has seen its stock trade within a 12-month range of $55.53 to $112.88. Institutional investors maintain strong conviction, with 97.3% of shares held by funds such as GAMMA Investing LLC (up 47.6% in Q4) and Farther Finance Advisors LLC (up 9,230.8% in Q2). On the research front, fifteen brokerages currently endorse the equity with Buy ratings and one with Sell, yielding a consensus target of $138.33. Recent adjustments include upward revisions from Robert W. Baird (+$46 from initial target) and Truist Financial (+$15), reflecting sustained optimism around Nuvalent’s lead candidates NVL-520 and NVL-655 and its precision oncology platform.